In millions, except per share items | Dec-31-22 | Sep-30-22 | Sep-05-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Sep-05-21 |
| 10-Q | 10-K | 8-K | 10-Q | 10-Q | 10-Q | 10-K | 8-K |
Revenues: |
Medical Device | 19.0 | 19.5 | | 17.5 | 18.5 | 16.9 | 17.4 | |
Royalties | | 9.5 | | 8.8 | 9.8 | | 8.9 | |
In Vitro Diagnostics | 5.9 | 6.5 | | 7.3 | 7.7 | 6.1 | 6.6 | |
Total revenues [+] | 24.9 | 26.0 | 26.0 | 24.9 | 26.1 | 23.0 | 24.0 | 24.0 |
Royalties | | | 9.5 | | | | | 8.9 |
Products | | | 14.4 | | | | | 12.5 |
Revenue growth [+] | 8.4% | 8.4% | 8.4% | 4.1% | -25.4% | 3.2% | 6.3% | |
Medical Device | 12.5% | 12.1% | | 4.6% | -33.9% | 4.4% | 1.3% | |
Royalties | | 7.2% | | 0.0% | -50.9% | | -10.1% | |
In Vitro Diagnostics | -3.0% | -1.3% | | 2.9% | 8.0% | -0.1% | 22.6% | |
Cost of goods sold | 5.3 | 5.6 | 5.6 | 5.1 | 5.1 | 4.5 | 4.2 | 4.2 |
Gross profit | 19.7 | 20.4 | 20.4 | 19.7 | 21.0 | 18.5 | 19.8 | 19.8 |
Gross margin | 78.9% | 78.5% | 78.5% | 79.3% | 80.4% | 80.5% | 82.6% | 82.6% |
Selling, general and administrative [+] | 12.7 | 17.5 | 13.8 | 12.9 | 11.1 | 11.7 | 23.9 | 7.9 |
General and administrative | | 17.5 | | | | | 23.9 | |
Other selling, general and administrative | | | | | | | | |
Research and development | 12.7 | 12.3 | | 13.0 | 13.7 | 11.7 | 10.7 | |
Other operating expenses | 2.1 | -2.6 | 13.2 | 1.0 | 1.1 | -1.4 | -13.7 | 12.4 |
EBITDA [+] | -5.8 | -4.4 | | -4.9 | -2.6 | -1.1 | 1.3 | |
EBITDA growth | 439.8% | -446.8% | 1252.4% | 6149.4% | -122.7% | -155.1% | -502.8% | |
EBITDA margin | -23.3% | -17.1% | -25.4% | -19.9% | -9.9% | -4.7% | 5.3% | -2.0% |
Depreciation | 1.1 | 1.2 | | 1.1 | 1.2 | 1.2 | 1.2 | |
EBITA | -6.9 | -5.7 | -6.6 | -6.0 | -3.8 | -2.3 | 0.1 | -0.5 |
EBITA margin | -27.8% | -21.9% | -25.4% | -24.3% | -14.6% | -9.8% | 0.3% | -2.0% |
Amortization of intangibles | 1.0 | 1.0 | | 1.1 | 1.1 | 1.2 | 1.2 | |
EBIT [+] | -7.9 | -6.7 | -6.6 | -7.1 | -4.9 | -3.5 | -1.1 | -0.5 |
EBIT growth | 129.7% | 493.5% | 1252.4% | 271.5% | -151.7% | -3811.8% | -48.6% | |
EBIT margin | -31.8% | -25.7% | -25.4% | -28.7% | -18.8% | -15.0% | -4.7% | -2.0% |
Non-recurring items | | | | | | | -0.5 | |
Interest expense, net [+] | | 0.3 | | 0.1 | 0.1 | | 0.1 | |
Interest expense | | 0.4 | | 0.1 | 0.1 | | 0.2 | |
Interest income | | 0.1 | | 0.0 | 0.0 | | 0.1 | |
Other income (expense), net [+] | -0.1 | 0.2 | -0.2 | 0.1 | 0.0 | -0.1 | 0.2 | -0.1 |
Gain (loss) on foreign currency transactions | | | | 0.1 | 0.0 | | 0.2 | |
Other | -0.1 | -0.3 | | | | -0.1 | -0.2 | |
Pre-tax income | -8.0 | -6.8 | -6.8 | -7.2 | -5.0 | -3.5 | -0.6 | -0.6 |
Income taxes | -0.2 | 7.9 | 7.9 | -1.5 | -0.9 | -0.7 | -0.3 | -0.3 |
Tax rate | 2.1% | | | 21.3% | 18.4% | 20.1% | 48.6% | 48.6% |
Net income | -7.8 | -14.7 | 0.0 | -5.7 | -4.1 | -2.8 | -0.3 | 0.0 |
Net margin | -31.5% | -56.7% | 0.0% | -22.7% | -15.6% | -12.2% | -1.2% | 0.0% |
|
Basic EPS [+] | ($0.56) | ($1.06) | $0.00 | ($0.41) | ($0.29) | ($0.20) | ($0.02) | $0.00 |
Growth | 176.8% | 4940.9% | | 70.8% | -149.9% | 910.7% | -90.3% | |
Diluted EPS [+] | ($0.56) | ($1.06) | $0.00 | ($0.41) | ($0.29) | ($0.20) | ($0.02) | $0.00 |
Growth | 176.8% | 5022.9% | | 70.8% | -150.7% | 910.7% | -90.3% | |
|
Shares outstanding (basic) [+] | 14.0 | 13.9 | 13.9 | 13.9 | 13.9 | 13.9 | 13.8 | 13.9 |
Growth | 0.8% | 1.1% | 0.7% | 0.7% | 1.2% | 1.5% | 1.6% | |
Shares outstanding (diluted) [+] | 14.0 | 13.9 | 13.9 | 13.9 | 13.9 | 13.9 | 14.0 | 13.9 |
Growth | 0.8% | -0.5% | 0.7% | 0.7% | -0.5% | 1.5% | 1.3% | |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |